Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

UK deal makes Novartis cancer cell therapy available to kids

Health authorities in England agreed with Novartis to fast-track access to the Swiss drugmaker’s expensive CAR-T cell therapy Kymriah and make it available to children and young people with aggressive leukemia when other drugs have failed.

Read More »

UK rejects Gilead’s CAR-T cancer cell therapy as too expensive

A cutting-edge CAR-T cell therapy for otherwise untreatable forms of blood cancer is too expensive to justify its use on Britain’s state-funded health service, the country’s healthcare cost agency NICE said.

Read More »

FDA approves Kala Pharma’s eye pain drug

The U.S. Food and Drug Administration approved Kala Pharmaceuticals Inc.’s treatment for reducing inflammation and pain following an eye surgery.

Read More »

AstraZeneca inhaler lags GSK drug in lung disease trial

A new AstraZeneca inhaler for chronic lung disease proved worse than a rival GlaxoSmithKline product in a clinical trial.

Read More »

Toxin at heart of drug recall shows holes in medical safety net

A toxin inadvertently produced in the manufacture of a widely prescribed medicine but not spotted for years raises questions about regulators’ ability to detect risks in a sprawling global drug supply chain increasingly reliant on factories in China.

Read More »

Tainted heart drug from second Chinese firm pulled off EU market

Heart drugs containing an active ingredient from a second Chinese company are being recalled from the European market after detection of a toxic impurity that may cause cancer.

Read More »

U.S. health secretary says agency has power to eliminate drug rebates

U.S. Health and Human Services Secretary Alex Azar said it was within his agency’s power to eliminate rebates on prescription drug purchases, a key element of the Trump administration’s plan to lower prescription medicine costs.

Read More »

Japan’s Eisai sets price tag of about $16,000 on liver cancer drug

Japan’s Eisai Co. Ltd. will price the company’s cancer drug Lenvima at about $16,000 for a month’s supply before discounts, after the U.S. Food and Drug Administration approved the product’s use in patients with a common form of liver cancer.

Read More »

Trump administration seeks cuts in production of abused opioids

The Trump administration said it was proposing that U.S. pharmaceutical companies cut production of the six most abused opioids by 10 percent next year.

Read More »

Biogen’s muscle drug Spinraza too costly for Britain

Biogen’s muscle disease treatment Spinraza has been deemed too expensive for use on Britain’s state-run health service, even after a price discount offered by the U.S. drugmaker.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2018 Focus: Top 50 Pharma, Company of the Year and more!

Subscribe

Ad Right Bottom